Pfizer Exceeds Earnings and Revenue Estimates, Reaffirms 2026 Outlook

Pfizer reported first-quarter earnings and revenue that exceeded Wall Street estimates, driven by growth in newer products and older top-selling drugs like Eliquis. The company reaffirmed its 2026 outlook despite declining revenue from its Covid vaccine and Paxlovid.

By Annika Kim Constantino · CNBC · May 5, 2026, 10:55 UTC

Pfizer Exceeds Earnings and Revenue Estimates, Reaffirms 2026 Outlook

Tickers: $MTSR $PFE

Topics: Covid-19 Earnings Eliquis Paxlovid Pfizer Pharmaceuticals Revenue

Read the full article at CNBC

More World news

Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC
Blackbaud Reports Third Quarter Revenue Growth and Strategic AI Integration Motley Fool · November 12, 2026, 17:53 UTC
Sprott Physical Copper Trust Reports Significant Increase in Q3 Net Income Seeking Alpha · November 12, 2026, 17:51 UTC